Brendan J. Nolan

Brendan J. Nolan

Auto-generated profile, based on publicly available information

Brendan J. Nolan

Trans Health Research Group, Department of Medicine (Austin Health), University of Melbourne, Heidelberg, Victoria, Australia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2019 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
PHPeter S Hamblin
Peter S Hamblin
RWRosemary Wong
Rosemary Wong
EEElif.I. Ekinci
Elif.I. Ekinci
SFSpiros Fourlanos
Spiros Fourlanos
SSSonali Shah
Sonali Shah
LBLeon Bach
Leon Bach
Context Diabetic ketoacidosis (DKA) has been associated with the use of sodium glucose cotransporter 2 inhibitors (SGLT2i). Objective To determine the incidence, characteristics and outcomes of DKA in SGLT2i-users vs non-users with type 2 diabetes. Design Retrospective, multi-center, controlled cohort study. Setting All public hospitals in Melbourne and Geelong (combined population 5 million), Australia, from 1 September 2015 - 31 October 2017. Patients Consecutive cases of DKA that developed in the community, or during the course of hospital admission, in patients with type 2 diabetes Main Outcome Measures In SGLT2i users vs non-users: (i) Odds ratio of DKA developing during hospital admission and (ii) Incidence of DKA Results There were 162 cases of DKA (37 SGLT2i users and 125 non-SGLT2i users) with a physician-adjudicated diagnosis of type 2 diabetes. Of these, DKA developed during the course of inpatient admission in 14 (38%) SGLT2i users vs two (2%) non-SGLT2i users, (odds ratio 37.4 [95% CI 8.0-175.9], p<0.0001). The incidence of diabetic ketoacidosis was 1.02/1000 (95% CI 0.74-1.41/1000) in SGLT2i users vs 0.69/1000 (0.58-0.82/1000) in non-SGLT2i users (odds ratio 1.48 (1.02-2.15), p=0.037). Fifteen SGLT2i users (41%) had peak blood glucose <250 mg/dl (14 mmol/l) compared to one (0.8%) non-SGLT2i user (p<0.001). Conclusions SGLT2i users were more likely to develop DKA as an inpatient compared to non-SGLT2i users. SGLT2i use was associated with a small, but significant increased risk of DKA.

13 July 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
ACAda Cheung
Ada Cheung
SZSav Zwickl
Sav Zwickl
KMKirsti Miller
Kirsti Miller
BNBrendan J Nolan
Brendan J Nolan
Alex WongAlex Wong
Alex Wong
NENir Eynon
Nir Eynon
Context The inclusion of transgender people in elite sport has been a topic of debate. This narrative review examines the impact of gender-affirming hormone therapy (GAHT) on physical performance, muscle strength, and markers of endurance. Evidence Acquisition MEDLINE and Embase were searched using terms to define the population (transgender), intervention (GAHT), and physical performance outcomes. Evidence Synthesis Existing literature comprises cross-sectional or small uncontrolled longitudinal studies of short duration. In nonathletic trans men starting testosterone therapy, within 1 year, muscle mass and strength increased and, by 3 years, physical performance (push-ups, sit-ups, run time) improved to the level of cisgender men. In nonathletic trans women, feminizing hormone therapy increased fat mass by approximately 30% and decreased muscle mass by approximately 5% after 12 months, and steadily declined beyond 3 years. While absolute lean mass remains higher in trans women, relative percentage lean mass and fat mass (and muscle strength corrected for lean mass), hemoglobin, and VO2 peak corrected for weight was no different to cisgender women. After 2 years of GAHT, no advantage was observed for physical performance measured by running time or in trans women. By 4 years, there was no advantage in sit-ups. While push-up performance declined in trans women, a statistical advantage remained relative to cisgender women. Conclusion Limited evidence suggests that physical performance of nonathletic trans people who have undergone GAHT for at least 2 years approaches that of cisgender controls. Further controlled longitudinal research is needed in trans athletes and nonathletes.

3 April 2023 in Climacteric
Verified
Journal Article
Open access
ACAda Cheung
Ada Cheung
BNB. J. Nolan
B. J. Nolan
SZSav Zwickl
Sav Zwickl
Gender affirming hormone therapy (GAHT) is used by many transgender people to reduce gender incongruence and improve psychological functioning. As GAHT shares many similarities with menopausal hormone therapy, clinicians supporting people through menopause are ideally placed to manage GAHT. This narrative review provides an overview of transgender health and discusses long-term effects of GAHT to consider when managing transgender individuals across the lifespan. Menopause is less relevant for transgender individuals who take GAHT (often given lifelong) to achieve sex steroid concentrations generally in the range of the affirmed gender. For people using feminizing hormone therapy, there is an elevated risk of venous thromboembolism, myocardial infarction, stroke and osteoporosis relative to cisgender individuals. For trans people using masculinizing hormone therapy, there is an increased risk of polycythemia, probable higher risk of myocardial infarction and pelvic pain which is poorly understood. Proactive mitigation of cardiovascular risk factors is important for all transgender people and optimization of bone health is important for those using feminizing hormones. With a lack of research to guide GAHT in older age, a shared decision-making approach is recommended for the provision of GAHT to achieve individual goals whilst minimizing potential adverse effects.

27 November 2020 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
BNBrendan J Nolan
Brendan J Nolan
BLBonnie Liang
Bonnie Liang
ACAda Cheung
Ada Cheung
Context: Preclinical data has shown progesterone metabolites improve sleep parameters through positive allosteric modulation of the γ-aminobutyric acid type A receptor. We undertook a systematic review and meta-analysis of randomized controlled trials to assess micronized progesterone treatment on sleep outcomes. Evidence Acquisition: Using preferred reporting items for systematic review and meta-analysis guidelines, we searched MEDLINE, Embase, PsycInfo, and the Cochrane Central Register of Controlled Trials for randomized controlled trials of micronized progesterone treatment on sleep outcomes up to March 31, 2020. This study is registered with the International Prospective Register of Systematic Reviews, number CRD42020165981. A random effects model was used for quantitative analysis. Evidence Synthesis: Our search strategy retrieved 9 randomized controlled trials comprising 388 participants. One additional unpublished trial was found. Eight trials enrolled postmenopausal women. Compared with placebo, micronized progesterone improved various sleep parameters as measured by polysomnography, including total sleep time and sleep onset latency, though studies were inconsistent. Meta-analysis of 4 trials favored micronized progesterone for sleep onset latency (effect size, 7.10; confidence interval [CI] 1.30, 12.91) but not total sleep time (effect size, 20.72; CI -0.16, 41.59) or sleep efficiency (effect size, 1.31; CI -2.09, 4.70). Self-reported sleep outcomes improved in most trials. Concomitant estradiol administration and improvement in vasomotor symptoms limit conclusions in some studies. Conclusions: Micronized progesterone improves various sleep outcomes in randomized controlled trials, predominantly in studies enrolling postmenopausal women. Further research could evaluate the efficacy of micronized progesterone monotherapy using polysomnography or validated questionnaires in larger cohorts.

1 April 2020 in Internal Medicine Journal
Verified
Journal Article
Closed access
PDF file
BNBrendan J. Nolan
Brendan J. Nolan
SLShalem Y. Leemaqz
Shalem Y. Leemaqz
OOOlivia Ooi
Olivia Ooi
PCPauline Cundill
Pauline Cundill
NSNicholas Silberstein
Nicholas Silberstein
ACAda Cheung
Ada Cheung

14 June 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MFMark Ng Tang Fui
Mark Ng Tang Fui
RHRudolf Hoermann
Rudolf Hoermann
BNBrendan Nolan
Brendan Nolan
MCMichelle Clarke
Michelle Clarke
JZJeffrey D. Zajac
Jeffrey D. Zajac
MGMathis Grossmann
Mathis Grossmann
To assess the effect of testosterone treatment on bone remodelling and density in dieting obese men, 100 obese men aged 53 years (interquartile range 47–60) with a total testosterone level <12 nmol/L receiving 10 weeks of a very low energy diet (VLED) followed by 46 weeks of weight maintenance were randomly assigned at baseline to 56 weeks of intramuscular testosterone undecanoate (n = 49, cases) or matching placebo (n = 51, controls). Pre-specified outcomes were between-group differences (mean adjusted difference, MAD) in serum c-telopeptide (CTx), N-terminal propeptide of type 1 procollagen (P1NP) and bone mineral density (BMD). At trial end, CTx was significantly reduced in men receiving testosterone compared to placebo, MAD −66 ng/L (95% CI −113, −18), p = 0.018, and this was apparent already after the 10 week VLED phase, MAD −63 ng/L (95% CI −108, −18), p = 0.018. P1NP was marginally increased after VLED, MAD +4.2 ug/L (95% CI −0.01, +8.4), p = 0.05 but lower at study end, MAD −5.6 ug/L (95% CI −10.1, −1.1), p = 0.03. No significant changes in sclerostin, lumbar spine BMD or femoral BMD were seen. We conclude that in obese men with low testosterone levels undergoing weight loss, bone remodelling markers are modulated in a way that may have favourable effects on bone mass.